Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
ODQ
75
CHF
CHF 75.00
In stock
AG-CR1-3500-M01010 mgCHF 75.00
AG-CR1-3500-M05050 mgCHF 250.00
| Product Details | |
|---|---|
| Synonyms | 1H-[1,2,4]Oxadiazole[4,3-a]quinoxalin-1-one |
| Product Type | Chemical |
| Properties | |
| Formula |
C9H5N3O2 |
| MW | 187.2 |
| CAS | 41443-28-1 |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to pale yellow solid. |
| Solubility | Soluble in DMSO (at least 5 mg/ml), ethyl acetate or 100% ethanol (1.2 mg/ml); insoluble in water. |
| Identity | Determined by 1H-NMR. |
| Other Product Data |
Store in the dark. Solutions may decompose slowly. |
| InChi Key | LZMHWZHOZLVYDL-UHFFFAOYSA-N |
| Smiles | O=C1ON=C2C=NC3=CC=CC=C3N12 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Potent and highly selective, irreversible inhibitor of soluble guanylyl cyclase (sGC). The binding is competitive with nitric oxide (NO) [1-5].
- Tool to elucidate the nitric oxide (NO)-cGMP pathway [1-5].
- Apoptosis inhibitor [6]
- Inhibits growth and migration of prostate cancer cells independent of its effects on GMP levels [6].
Product References
- Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase: C.L. Boulton, et al.; Neuroscience 69, 699 (1995)
- Novel guanylyl cyclase inhibitor, ODQ reveals role of nitric oxide, but not of cyclic GMP in endothelin-1 secretion: F. Brunner, et al.; FEBS Lett. 376, 262 (1995)
- Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one: J. Garthwaite, et al.; Mol. Pharmacol. 48, 184 (1995)
- Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase: A. Schrammel, et al.; Mol. Pharmacol. 50, 1 (1996)
- Inhibition of Soluble Guanylate Cyclase by ODQ: Y. Zhao, et al.; Biochemistry 39, 10848 (2000)
- cGMP-independent anti-tumour actions of the inhibitor of soluble guanylyl cyclase, ODQ, in prostate cancer cell lines: G. Haramis, et al.; Br. J. Pharmacol. 155, 804 (2008)
Related Products
